Aerovate Therapeutics Inc
NASDAQ:AVTE
Aerovate Therapeutics Inc
NASDAQ:AVTE
Price:
20.29 USD
-2.22%
Market Closed
Updated:
May 5, 2024
Aerovate Therapeutics Inc
Cash from Financing Activities
|
Aerovate Therapeutics Inc
Cash from Financing Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Aerovate Therapeutics Inc
NASDAQ:AVTE
|
Cash from Financing Activities
$46m
|
CAGR 3-Years
73%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Aerovate Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
46m
USD
46m
USD
Based on the financial report for Dec 31, 2023, Aerovate Therapeutics Inc's Cash from Financing Activities amounts to 46m USD.
What is Aerovate Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
73%
73%
Over the last year, the Cash from Financing Activities growth was 11 399%. The average annual Cash from Financing Activities growth rates for Aerovate Therapeutics Inc have been 73% over the past three years .
You don't have any saved screeners yet
